Education 【 display / non-display 】

Education 【 display / non-display 】

• 2001

  -

  2005

  Sapporo Medical University   Graduate School of Medicine  

• 1991

  -

  1997

  Sapporo Medical University   医学部   医学科  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 2005.03   札幌医科大学 大学院医学研究科   医学博士

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2020.10

  -

  Now

  Sapporo Medical University   医学部放射線医学講座   准教授

  准教授

• 2011.04

  -

  2020.09

  Sapporo Medical University   医学部放射線医学講座   講師

  講師

• 2007.04

  -

  2011.03

  Sapporo Medical University   医学部放射線医学講座   助教

  助教

• 2005.08

  -

  2007.03

  Sapporo Medical University   医学部放射線医学講座   助手

  助手

• 1999.04

  -

  2005.07

  札幌医科大学附属病院   放射線科   診療医

  診療医

display all >>

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 2022.01

  -

  Now

  日本バイオセラピィ学会

• 2021.08

  -

  Now

  日本放射線影響学会

• 2021.01

  -

  Now

  日本免疫治療学会

• 2017.07

  -

  Now

  日本癌治療学会

• 2017.05

  -

  Now

  日本膵臓学会

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Radiology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• 札幌医科大学医学部   放射線医学講座   准教授  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• 放射線腫瘍学

• 腫瘍免疫と放射線治療

• リキッドバイオプシー

• DNA損傷修復

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy.

  Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Yu Takada, Masakazu Hori, Katsutoshi Miura, Mio Kitagawa, Toshio Gocho, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

  Japanese journal of clinical oncology ( Oxford University Press (OUP) )  50 ( 11 ) 1290 - 1297  2020.10  [Refereed]  [International journal]

  Authorship：   Lead author  , Corresponding author

  　View Summary

  OBJECTIVE: To evaluate proteins related to tumor immune response and treatment outcome from radiotherapy for uterine cervical cancer patients. METHODS: We performed a retrospective immunohistochemical staining of 81 patients with uterine cervical cancer who underwent definitive radiotherapy. We examined the expression of programmed death ligand 1, human leukocyte antigen class I, tumor-infiltrating CD8+, and forkhead box P3+ (FoxP3+) T cells in tumor tissues. RESULTS: In biopsy specimen, patients with a higher number of CD8+ T cells and FoxP3+ T cells had a better disease-specific survival than patients with a lower number of CD8+ T cells and FoxP3+ cells (P = 0.018 and P = 0.009). Multivariate analysis showed that equivalent dose in 2 Gy fractions (EQD2) of the minimum dose to 90% of the high-risk clinical target volume, FoxP3+ T cells and expression of human leukocyte antigen class I were significant prognostic factors. When the EQD2 is 70 Gy or more, a higher local control rate is obtained regardless of the number of CD8- or FoxP3-positive cells. When EQD2 is <70 Gy, the number of CD8-positive cells has a significant impact on treatment outcome: the recurrence rate (local recurrence rate + distant metastasis rate) was 46.2% in the group with a CD8 value of 230 or higher, whereas the recurrence rate was 75.7% in the group with a CD8 value of less than 230. CONCLUSION: The combination of CD8 or FoxP3 with EQD2 can be potentially useful to predict the treatment results of radiotherapy for cervical cancer, leading to individualized optimal selection of treatment for cervical cancer.

  DOI PubMed

• Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer.

  Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Yuuki Fukushima, Masakazu Hori, Katsutoshi Miura, Yu Takada, Kensei Nakata, Koh-Ichi Sakata

  Journal of radiation research   61 ( 2 ) 265 - 274  2020.03  [Refereed]  [International journal]

  　View Summary

  Combining external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT) is important for definitive treatment of cervical cancer. In cervical cancer patients receiving radiotherapy, we evaluated treatment outcomes in relation to dose-volume histogram parameters, including the computed tomography (CT)-based high-risk clinical target volume (HR-CTV) for ICBT. Between 2010 and 2015, 89 consecutive cervical cancer patients were mostly treated with 40 Gy of EBRT in 20 fractions and 18 Gy of ICBT prescribed to point A in 3 fractions. CT scans were obtained during ICBT. The HR-CTV D90 was calculated and the total doses of ICBT and EBRT were converted to the equivalent dose in 2 Gy fractions (EQD2). When the patients were divided into four groups according to EQD2 of the HR-CTV D90, the 3-year local recurrence-free survival rates were 95.2, 78.4, 52.7 and 42.9% for patients receiving >80 , 70-80 , 60-70 and <60 Gy, respectively. There was a significant negative correlation between EQD2 of the HR-CTV D90 and the HR-CTV volume at first ICBT (r = -0.713). Local recurrence was more frequent when the HR-CTV volume was ≥22 cc and EQD2 of the HR-CTV D90 was <70 Gy. Multivariate analysis showed that EQD2 of the HR-CTV D90 and concurrent chemotherapy (≥4 cycles) were significant determinants of overall survival. HR-CTV D90 was an important prognostic indicator for local recurrence. HR-CTV D90 >70 Gy is required for the better local control, especially in patients with a larger HR-CTV (≥22 cc at initial ICBT).

  DOI PubMed

• Prediction of acute gastrointestinal and genitourinary radiation toxicity in prostate cancer patients using lymphocyte microRNA.

  Masanori Someya, Masakazu Hori, Toshio Gocho, Kensei Nakata, Takaaki Tsuchiya, Mio Kitagawa, Tomokazu Hasegawa, Yuuki Fukushima, Koh-Ichi Sakata

  Japanese journal of clinical oncology   48 ( 2 ) 167 - 174  2018.02  [Refereed]  [International journal]

  　View Summary

  Background: To search for novel biomarkers that can predict acute radiation toxicity, we conducted microRNA expression analysis of peripheral blood lymphocytes (PBLs). Methods: The discovery cohort was 69 patients with localized adenocarcinoma of the prostate who received intensity-modulated radiation therapy between October 2007 and October 2010. The validation cohort was 72 patients treated with low-dose-rate brachytherapy between May 2008 and March 2014. After13 microRNAs were selected by TaqMan® Array analysis in a preliminary experiment, expression of these microRNAs in all samples was analyzed by RT-PCR. Results: In the discovery cohort, the average prostate volume, the rectal volume receiving 70 Gy, and expression of miR-410 and miR-221 were significant risk factors for Grade 1-2 gastrointestinal toxicity. Receiver operating characteristic analysis showed that the area under the curve (AUC) was 0.807. The maximum dose to the urinary bladder, prostate volume, pretreatment urinary function score, and miR-99a and miR-221 expression were risk factors for Grade 2 genitourinary toxicity. The corresponding AUC was 0.796. In the validation cohort, reproducibility of these markers was confirmed for gastrointestinal toxicity, but not for genitourinary toxicity. Conclusion: Combining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer.

  DOI PubMed

• Local tumor control and DNA-PK activity of peripheral blood lymphocytes in prostate cancer patients receiving radiotherapy.

  Masanori Someya, Tomokazu Hasegawa, Masakazu Hori, Yoshihisa Matsumoto, Kensei Nakata, Naoya Masumori, Koh-Ichi Sakata

  Journal of radiation research   58 ( 2 ) 225 - 231  2017.03  [Refereed]  [International journal]

  　View Summary

  Repair of DNA damage is critical for genomic stability, and DNA-dependent protein kinase (DNA-PK) has an important role in repairing double-strand breaks. We examined whether the DNA-PK activity of peripheral blood lymphocytes (PBLs) was related to biochemical (prostate-specific antigen: PSA) relapse and radiation toxicity in prostate cancer patients who have received radiotherapy. A total of 69 patients with localized adenocarcinoma of the prostate participated in this study. Peripheral blood was collected 2 years or later after radiotherapy and centrifuged, then DNA-PK activity was measured by a filter binding assay. The high DNA-PK activity group had a significantly higher PSA relapse-free survival rate than the low DNA-PK activity group. The 10-year PSA relapse-free survival was 87.0% in the high DNA-PK activity group, whereas it was 52.7% in the low DNA-PK activity group. Multivariate analysis showed the Gleason score and the level of DNA-PK activity were significant predictors of PSA relapse after radiotherapy. In addition, the low DNA-PK activity group tended to have a higher incidence of Grade 1-2 urinary toxicity than the high DNA-PK activity group. Prostate cancer patients with low DNA-PK activity had a higher rate of PSA relapse and a higher incidence of urinary toxicity. DNA-PK activity in PBLs might be a useful marker for predicting PSA relapse and urinary toxicity, possibly contributing to personalized treatment of prostate cancer.

  DOI PubMed

• Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy for prostate cancer.

  Masanori Someya, Hiroyuki Yamamoto, Masanori Nojima, Masakazu Hori, Kunihiko Tateoka, Kensei Nakata, Masaru Takagi, Masato Saito, Naoki Hirokawa, Takashi Tokino, Koh-Ichi Sakata

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology ( ELSEVIER IRELAND LTD )  115 ( 2 ) 235 - 9  2015.05  [Refereed]  [International journal]

  　View Summary

  BACKGROUND AND PURPOSE: Late rectal bleeding is one of the severe adverse events after radiotherapy for prostate cancer. New biomarkers are needed to allow a personalized treatment. MATERIALS AND METHODS: Four patients each with grade 0-1 or grade 2-3 rectal bleeding were randomly selected for miRNA array to examine miRNA expression in peripheral blood lymphocytes (PBLs). Based on results of miRNA array, 1 of 348 miRNAs was selected for microRNA assays. Then, expression of DNA-dependent protein kinase mRNA and miR-99a was analyzed in the PBLs of 97 patients. PBLs were exposed to 4Gy of X-ray ex-vivo. RESULTS: In the discovery cohort, grade 2-3 rectal bleeding was significantly higher in the Ku80 <1.09 expression group compared with ⩾1.09 group (P=0.011). In radiation-induced expression of miR-99a, grade 2-3 rectal bleeding was significantly higher in the miR-99a IR(+)/IR(-) >0.93 group compared with ⩽0.93 group (P=0.013). Most patients with grade 2-3 rectal bleeding were in the group with low Ku80 and high miR-99a expression. In the validation cohort, similar results were obtained. CONCLUSION: A combination of low Ku80 expression and highly-induced miR-99a expression could be a promising marker for predicting rectal bleeding after radiotherapy.

  DOI PubMed

display all >>

Books and Other Publications 【 display / non-display 】

Books and Other Publications 【 display / non-display 】

• 患者・市民のための膵がん診療ガイド

  日本膵臓学会, 日本膵臓学会膵癌診療ガイドライン改訂委員会( Part： Contributor, 放射線治療)

  金原出版  2023.05 ISBN: 9784307204606

• 密封小線源治療診療・物理QAマニュアル : 小線源治療部会ガイドラインに基づく

  日本放射線腫瘍学会小線源治療部会( Part： Contributor, 放射線生物学)

  金原出版  2022.05 ISBN: 9784307071253

• 患者さんと家族のための放射線治療Q&A 2020年版

  日本放射線腫瘍学会( Part： Contributor)

  金原出版  2020.09 ISBN: 9784307071154

• 患者・市民・医療者をつなぐ膵がん診療ガイドライン2019の解説

  日本膵臓学会, 日本膵臓学会膵癌診療ガイドライン改訂委員会( Part： Contributor, 放射線治療)

  金原出版  2020.07 ISBN: 9784307204163

• 患者さんと家族のための放射線治療Q&A 2015年版

  日本放射線腫瘍学会( Part： Contributor)

  金原出版  2015.11 ISBN: 9784307071017

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 子宮頸癌の放射線治療成績と末梢血リンパ球のDNA-PK活性の関係

  染谷 正則, 松本 健一, 福島 悠希, 後町 俊夫, 土屋 高旭, 長谷川 智一, 北川 未央, 堀 正和, 中田 健生, 坂田 耕一

  Japanese Journal of Radiology ( (公社)日本医学放射線学会 )  36 ( Suppl. ) 11 - 11  2018.02

• 前立腺癌放射線治療患者のリンパ球を用いた消化管および尿路の急性期有害事象予測

  染谷 正則, 堀 正和, 長谷川 智一, 中田 健生, 土屋 高旭, 北川 未央, 後町 俊夫, 福島 悠希, 舛森 直哉, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  55回   O7 - 1  2017.10

• 前立腺癌根治照射後の直腸障害とDVH解析

  染谷 正則, 中田 健生, 三浦 勝利, 堀 正和, 坂田 耕一

  Japanese Journal of Radiology ( (公社)日本医学放射線学会 )  33 ( Suppl. ) 5 - 5  2015.02

• PARP阻害剤オラパリブの放射線増感効果のメカニズム

  染谷 正則, 三浦 勝利, 坂田 耕一, 中田 健生, 堀 正和, 畠中 正光

  Japanese Journal of Radiology ( (公社)日本医学放射線学会 )  32 ( Suppl. ) 5 - 5  2014.02

• DNA修復の阻害による放射線増感効果の検討

  染谷 正則, 三浦 勝利, 高木 克, 坂田 耕一, 晴山 雅人

  Japanese Journal of Radiology ( (公社)日本医学放射線学会 )  31 ( Suppl.I ) 12 - 12  2013.02

display all >>

Other 【 display / non-display 】

Other 【 display / non-display 】

• 日本膵臓学会認定指導医

  2023.01

  -

  Now

  　View Summary

  1096号

• 日本がん治療認定機構 がん治療認定医

  2012.04

  -

  Now

  　View Summary

  11100995号

• 医学博士取得

  2005.03

  -

  Now

  　View Summary

  札幌医科大学 第2272号

• 日本医学放射線学会 日本放射線腫瘍学会 放射線治療専門医

  2002.08

  -

  Now

  　View Summary

  R10194RO

Awards 【 display / non-display 】

Awards 【 display / non-display 】

• 生物部会賞受賞

  2016.07   第54回JASTRO生物部会学術大会   前立腺癌放射線治療患者のリンパ細胞を用いた急性期有害事象予測

• 放射線影響研究奨励賞受賞

  2009.10   放射線影響協会   DNA二重鎖切断修復酵素と放射線感受性および癌罹患リスクに関する研究

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• 腫瘍免疫のリアルタイムモニタリングによる個別化放射線治療の確立

  基盤研究(C)

  Project Year :

  2023.04

  -

  2026.03

   

  土屋 高旭、染谷 正則

• Practical application of individualized radiotherapy using liquid biopsy

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2021.04

  -

  2024.03

   

  染谷 正則, 池内 佑太郎, 小塚 陽, 後町 俊夫

  　View Summary

  ＜目的＞治療効果向上と有害事象軽減を目指した「個別化放射線治療」を実践するために、局所進行悪性腫瘍に対し、末梢リンパ球や血中の腫瘍由来エクソソームに存在する、mRNAやmiRNAの発現パターンを調べ、放射線治療効果を予測する。またDNA修復能の指標として末梢リンパ球の放射線誘発ガンマH2AXフォーカスを測定する事で有害事象を予測する。これらの手法を用いて個々の患者毎の特性に合わせて線量分割や照射体積を調整する。 ＜方法＞以下に示す方法で、末梢血リンパ細胞およびエクソソーム内のmRNA/miRNA発現パターンや末梢血リンパ細胞の放射線誘発ガンマH2AXフォーカス形成能を測定した。 (A) 血漿中からのエクソソームの抽出とRNA分離・発現解析は、QIAGEN社のexoRNeasy plasma kitを用いた。バイオアナライザーを用いてRNA濃度と目的となる２０‐２５塩基配列程度のmiRNAが取れている事を確認した。QIAseq miRNA Library Kitを用いてRNA解析を行なった。これまで子宮頸がん36例からのエクソソーム抽出を行い、再発リスクとなる候補miRNAを抽出する。 (B) 末梢血リンパ細胞の放射線誘発ガンマH2AXフォーカス計測は、ex vivoでX線を１Gy照射し、３０分後および４時間後にリンパ球を分離・固定を行い、スライドグラス上で蛍光免疫染色を行い、蛍光顕微鏡下にフォーカス数をカウントし、その変化率を計算してDNA修復能力を数値化する。

• 放射線治療に関わるトランスレーショナルリサーチ実施体制構築

  Project Year :

  2021.04

  -

  2024.03

   

  Authorship： Coinvestigator(s)

• IMRTを利用した頭髪温存全脳照射

  基盤研究(C)

  Project Year :

  2020.04

  -

  2025.03

   

  斉藤 アンネ優子, 大西 洋, 野澤 桂子, 染谷 正則

  　View Summary

  前半の全脳照射後の頭髪の状況の多施設共同観察研究が進行中である。5施設から、合計44例の登録をいただいた。現状は、頭皮の評価は行わず、症例集積の状況である。 症例集積が予定より遅い理由として、 COVIDの影響ももちろんあるが、適格条件が厳しすぎること、全脳照射後、頭皮の撮影のために来院する回数が多く、条件を満たせないため参加を躊躇するケースも多いことなどが挙げられ、zoomで3回の会議を行い、照射線量の縛りを外すことで適格条件をゆるめること、また、通院回数は同じままで、ただし、すべての通院を義務化するわけではなく、患者さんが可能な範囲で通院していただく状況に、条件をゆるめた。 また、当初、８０例集積としたが、これは、全脳照射の患者の全身状態が悪いことを踏まえ、半数が脱落することを想定した数である。今までの症例を確認すると脱毛のピークはほとんどの症例で8週目あたりであり、8週目までの経過観察が行えた症例を評価可能と判定することとした。研究実施期間の猶予が少ないことを考えると、当初の予定どおり愚直に８０例を蓄積するのではなく、評価可能例が４０例になった段階で、次の研究に進む方針へ変更することが得策と思われた。 これを踏まえて研究実施計画書を書き直し、順天堂浦安病院の倫理委員会に提出した。また、IMRTを利用した頭皮温存についても、実施計画書の作成を開始した。

• Application of Liquid Biopsy for Personalized Radiation Therapy

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2018.04

  -

  2021.03

   

  Someya Masanori

  　View Summary

  In order to realize "personalized radiotherapy", we used a technique called "liquid biopsy" to examine the nucleic acids and proteins of tumor-derived exosomes in plasma, and applied it to the prediction of radiosensitivity of cancer. Blood samples were collected from a total of 150 patients with cervical, rectal, anal and pancreatic cancers treated with abdominal to pelvic radiotherapy, and plasma and lymphocyte samples were isolated. DNA-PK activity of lymphocytes and radiation-induced gamma H2AX focus was measured, and exosomal microRNA expression analysis in plasma was performed. Based on the results of the treatment outcome and adverse event surveys for each cancer and the results of lymphocyte DNA-PK activity and radiation-induced gamma-H2AX focus measurements, we showed that exosomal microRNAs in plasma are useful for predicting the effects of radiotherapy and that lymphocyte DNA-PK activity may be useful for predicting late adverse events after radiotherapy.

display all >>

Presentations 【 display / non-display 】

Presentations 【 display / non-display 】

• Relationship between tumor immunity and radiotherapy effects in HPV associated cancer.

  Masanori Someya  [Invited]

  第63回日本放射線影響学会 

  Presentation date： 2020.10

  Event date：

  2020.10

  　

  　

• HPV関連癌における腫瘍免疫と放射線治療効果との関係

  染谷 正則  [Invited]

  第33回日本放射線腫瘍学会学術大会 

  Presentation date： 2020.10

  Event date：

  2020.10

  　

  　

• 放射線治療の最近の話題

   [Invited]

  日本癌治療学会第25回アップデート教育コース 

  Presentation date： 2023.05

• 個別化放射線治療を目指した、リンパ球 RNA 発現解析による有害事象予測

  染谷正則  [Invited]

  札幌冬季がんセミナー 

  Presentation date： 2017.01

• Relationship between tumor immunity and radiotherapy effects in HPV associated cancer.

  Masanori Someya  [Invited]

  第56回日本医学放射線学会秋季大会 

  Presentation date： 2020.10

display all >>

Teaching Experience 【 display / non-display 】

Teaching Experience 【 display / non-display 】

• 放射線治療学  

  札幌医科大学医学修士  

  2022.06

  -

  Now

   

• 放射線物理学  

  札幌医科大学医学部医学科  

  2020.10

  -

  Now

   

• 放射線治療学  

  札幌医科大学医学部医学科  

  2011.09

  -

  Now

   

Committee Memberships 【 display / non-display 】

Committee Memberships 【 display / non-display 】

• 2023.06

  -

  Now

    幹事

• 2022.06

  -

  Now

    評議員

• 2022.04

  -

  Now

    運営委員ジュニア

• 2017.09

  -

  Now

    膵癌治療ガイドライン改訂委員

• 2010.10

  -

  Now

    JASTRO代議員